Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II results presented for TAK-954 in patients with enteral feeding intolerance

June 7, 2018

Athersys expands its collaboration with Healios

June 7, 2018

EMA grants PRIME designation for dilanubicel

June 7, 2018

FDA grants orphan drug designation to TransCon PTH

June 7, 2018

4D pharma and MSD collaborate to study Keytruda and MRx-0518 combination in solid tumors

June 7, 2018

Positive results presented from ongoing phase I trial of PTI-801 in patients with CF

June 7, 2018

First healthy volunteers enrolled in phase I study of BTRX-335140

June 7, 2018

ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients

June 7, 2018

Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL

June 7, 2018

Merck & Co. synthesizes new FXIIa inhibitors

June 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...